BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 20087864)

  • 1. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.
    Lacroix J; Leuchs B; Li J; Hristov G; Deubzer HE; Kulozik AE; Rommelaere J; Schlehofer JR; Witt O
    Int J Cancer; 2010 Sep; 127(5):1230-9. PubMed ID: 20087864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner.
    Mazar J; Brooks JK; Peloquin M; Rosario R; Sutton E; Longo M; Drehner D; Westmoreland TJ
    Cancer Res Commun; 2024 Jan; 4(1):65-80. PubMed ID: 38214542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses.
    Vollmers EM; Tattersall P
    Virology; 2013 Nov; 446(1-2):37-48. PubMed ID: 24074565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.
    Angelova A; Rommelaere J; Ungerechts G
    Pathogens; 2024 Feb; 13(3):. PubMed ID: 38535528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
    Turnbull S; West EJ; Scott KJ; Appleton E; Melcher A; Ralph C
    Viruses; 2015 Dec; 7(12):6291-312. PubMed ID: 26633468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1.
    Hauswirth P; Graber P; Buczak K; Mancuso RV; Schenk SH; Nüesch JPF; Huwyler J
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress of oncolytic virotherapy for neuroblastoma.
    Chen XT; Dai SY; Zhan Y; Yang R; Chen DQ; Li Y; Zhou EQ; Dong R
    Front Pediatr; 2022; 10():1055729. PubMed ID: 36467495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding recombinant AAVs to the cancer therapeutics mix.
    Mulcrone PL; Herzog RW; Xiao W
    Mol Ther Oncolytics; 2022 Dec; 27():73-88. PubMed ID: 36321134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression.
    Hanisch D; Krumm A; Diehl T; Stork CM; Dejung M; Butter F; Kim E; Brenner W; Fritz G; Hofmann TG; Roos WP
    Cell Death Dis; 2022 Apr; 13(4):293. PubMed ID: 35365623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review).
    Sevastre AS; Costachi A; Tataranu LG; Brandusa C; Artene SA; Stovicek O; Alexandru O; Danoiu S; Sfredel V; Dricu A
    Exp Ther Med; 2021 Dec; 22(6):1408. PubMed ID: 34676001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
    Kulkarni A; Ferreira T; Bretscher C; Grewenig A; El-Andaloussi N; Bonifati S; Marttila T; Palissot V; Hossain JA; Azuaje F; Miletic H; Ystaas LAR; Golebiewska A; Niclou SP; Roeth R; Niesler B; Weiss A; Brino L; Marchini A
    Nat Commun; 2021 Jun; 12(1):3834. PubMed ID: 34158478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
    Oh CM; Chon HJ; Kim C
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24.
    Mazar J; Li Y; Rosado A; Phelan P; Kedarinath K; Parks GD; Alexander KA; Westmoreland TJ
    PLoS One; 2018; 13(7):e0200358. PubMed ID: 30044847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro.
    Geiss C; Kis Z; Leuchs B; Frank-Stöhr M; Schlehofer JR; Rommelaere J; Dinsart C; Lacroix J
    Viruses; 2017 Oct; 9(10):. PubMed ID: 29039746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.
    Takenouchi A; Saito K; Saito E; Saito T; Hishiki T; Matsunaga T; Isegawa N; Yoshida H; Ohnuma N; Shirasawa H
    Pediatr Surg Int; 2015 Dec; 31(12):1151-9. PubMed ID: 26298056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.
    Angelova AL; Geletneky K; Nüesch JP; Rommelaere J
    Front Bioeng Biotechnol; 2015; 3():55. PubMed ID: 25954743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1.
    Geletneky K; Leoni AL; Pohlmeyer-Esch G; Loebhard S; Baetz A; Leuchs B; Roscher M; Hoefer C; Jochims K; Dahm M; Huber B; Rommelaere J; Krebs O; Hajda J
    Comp Med; 2015 Feb; 65(1):23-35. PubMed ID: 25730754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.